For Q1 FY2026 ended March 31, 2026, Establishment Labs reported revenue of $59.9M, up 44.7% year-over-year. Net loss was $13.4M, improving 35.4% from the prior year. Operating loss was $6.5M, a 61.6% improvement. Diluted EPS was -$0.45, compared to -$0.70 a year ago. Cash stood at $68.1M, equity at $14.8M, and long-term debt at $248.6M.
•Revenue grew 44.7% YoY to $59.9M.
•Net loss narrowed 35.4% to $13.4M.
•Operating loss improved 61.6% to $6.5M.
•Diluted EPS was -$0.45, up from -$0.70.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Establishment Labs Holdings Inc., a medical technology company manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States.
The company offers silicone gel-filled breast implants under the Motiva Implants brand, as well as breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
What does Establishment Labs Holdings Inc. (ESTA) do?
Establishment Labs Holdings Inc. is a medical technology company that manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries. The company's primary product is silicone gel-filled breast implants sold under the Motiva Implants brand. In addition to breast implants, the company also offers breast tissue expanders. These products are used by physicians, hospitals, and clinics for both cosmetic enhancement and reconstructive procedures following mastectomy or injury. The company operates globally, serving markets in Europe, the Middle East, Africa, Latin America, Asia, and the United States.
Where is Establishment Labs Holdings Inc. (ESTA) listed and what currency is used?
Establishment Labs Holdings Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ESTA. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company with a global presence, the use of USD aligns with its headquarters in Austin, Texas, and provides consistency for investors trading on US exchanges.
What sector and industry does Establishment Labs Holdings Inc. (ESTA) operate in?
Establishment Labs Holdings Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. This classification reflects the company's focus on developing and manufacturing medical devices for surgical procedures. The Medical Devices industry encompasses a wide range of products used in diagnosis, monitoring, and treatment, and Establishment Labs specializes in devices for breast surgery, including implants and tissue expanders. The company's products are regulated medical devices requiring compliance with health authority standards.
Where is Establishment Labs Holdings Inc. (ESTA) headquartered and what markets does it serve?
Establishment Labs Holdings Inc. is headquartered in Austin, Texas, United States. The company was incorporated in 2004 and has since expanded its operations globally. It serves markets across Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company sells its products through a combination of distributors and its direct sales force, reaching physicians, hospitals, and clinics worldwide. This broad geographic presence allows Establishment Labs to cater to both aesthetic and reconstructive breast surgery needs internationally.
How does Establishment Labs Holdings Inc. (ESTA) generate revenue?
Establishment Labs Holdings Inc. generates revenue by manufacturing and selling medical devices for breast surgery. Its main product line is silicone gel-filled breast implants marketed under the Motiva Implants brand, along with breast tissue expanders used in reconstructive procedures. The company sells these products to physicians, hospitals, and clinics through two primary channels: a direct sales force and a network of distributors. By serving customers across multiple regions—including Europe, the Middle East, Africa, Latin America, Asia, and the United States—the company diversifies its revenue streams. The business model focuses on providing high-quality medical devices for both aesthetic enhancement and reconstructive surgery, catering to a global demand for breast implant procedures.